Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen

Fig. 2

Sequence of tumor irradiation and vaccine for the treatment of Renca-MUC1 tumors. Established Renca-MUC1 tumors were treated with 8 Gy radiation (Rad) and MVA-MUC1-IL-2 vector (Vaccine) administered peritumorally at 107 PFU in 25 μl S08 buffer. a. Schedule 1: Sequence of radiation followed by vaccine. Tumors were irradiated on day 11, followed by vaccine on day 12 and 17. Schedule 2: Sequence of vaccine followed by radiation. Tumors were first injected with vaccine on day 9, then were irradiated two days later on day 11, followed by a second treatment of vaccine on day 17. b. Tumor growth curves. B1. Control (Control) untreated mice. B2. Radiation treatment alone. B3. Schedule 1 sequence of radiation followed by vaccine. B4. Schedule 2 sequence of vaccine followed by radiation. Each symbol represents the tumor volume of individual mice with 8 mice per group for control and 18 mice per treatment group B2, B3, and B4 at different time points post cell injection. c. Survival curves. In a separate experiment identical to that shown in A, established Renca-MUC1 tumors were treated with 8 Gy radiation (Rad) and MVA-MUC1-IL-2 vector (Vaccine) administered peritumorally at 107 PFU using either Schedule 1 of radiation followed by two vaccine treatments or Schedule 2 of vaccine followed by radiation and a second vaccine treatment. Mice were followed for survival (n = 8 mice for control or radiation alone and n = 12 mice for combined radiation and vaccine)

Back to article page